{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:18:11Z","timestamp":1791487091691,"version":"4.3.4"},"reference-count":312,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T00:00:00Z","timestamp":1542499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Taiwan Association for the Study of Liver"},{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["106-2314-B-182A-105-MY2"],"award-info":[{"award-number":["106-2314-B-182A-105-MY2"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jfma.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:53:02Z","timestamp":1544057582000},"page":"7-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"P1","title":["Taiwan consensus statement on the management of chronic hepatitis B"],"prefix":"10.1016","volume":"118","author":[{"given":"Rong-Nan","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5425","authenticated-orcid":false,"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Mo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-9372","authenticated-orcid":false,"given":"Yun-Fan","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2018.11.008_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1440-1746.2008.05385.x","article-title":"Understanding the immunopathogenesis of chronic hepatitis B: an Asian prospective","volume":"23","author":"Tan","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2018.11.008_bib6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840050315","article-title":"Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum","volume":"5","author":"Chu","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","article-title":"Hepatitis B: reflection on the current approach to antiviral therapy","volume":"48","author":"Zoulim","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.bpg.2008.11.003","article-title":"Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success","volume":"22","author":"Chien","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"EASL","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogues therapy in patients with chronic hepatitis B:clinical outcomes and durability","volume":"63","author":"Kim","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib16","first-page":"783","article-title":"Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections","volume":"104","author":"Liu","year":"2005","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2018.11.008_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12072-009-9147-9","article-title":"Dual chronic hepatitis B virus and hepatitis C virus infection","volume":"3","author":"Liu","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.24500","article-title":"Fighting against viral hepatitis: lessons from Taiwan","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1053\/jhep.2002.36509","article-title":"HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course","volume":"36","author":"Sagnelli","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jfma.2018.11.008_bib22","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2011.36.2335","article-title":"Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C","volume":"29","author":"Huang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib24","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMp1201796","article-title":"HIV-HBV coinfection\u2014a global challenge","volume":"366","author":"Kourtis","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib25","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1002\/hep.22883","article-title":"Hepatitis B and human immunodeficiency virus coinfection","volume":"49","author":"Thio","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib26","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/infdis\/163.5.1138","article-title":"The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus Carrier state","volume":"163","author":"Bodsworth","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib27","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.510290447","article-title":"Influence of human immunodeficiency virus infection onchronic hepatitis B in homosexual men","volume":"29","author":"Colin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/420744","article-title":"Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic","volume":"38","author":"Sheng","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00002030-199206000-00008","article-title":"Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS","volume":"6","author":"Eskild","year":"1992","journal-title":"AIDS"},{"key":"10.1016\/j.jfma.2018.11.008_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-117-10-837","article-title":"Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival","volume":"117","author":"Scharschmidt","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jit299","article-title":"Hepatitis B virus (HBV) coinfection accelerates immunological progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection","volume":"208","author":"Tsai","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/infdis\/jir720","article-title":"Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters","volume":"205","author":"Chun","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","article-title":"Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog","volume":"48","author":"Tseng","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib36","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3748\/wjg.v20.i24.7686","article-title":"Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib37","doi-asserted-by":"crossref","first-page":"a021436","DOI":"10.1101\/cshperspect.a021436","article-title":"HBV genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","article-title":"Hepatitis B viral factors and treatment responses in chronic hepatitis B","volume":"112","author":"Lin","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2018.11.008_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0033-1345716","article-title":"Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J","volume":"33","author":"Liu","year":"2013","journal-title":"Seminar Liver Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/JCM.40.4.1207-1209.2002","article-title":"Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection","volume":"40","author":"Kao","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jfma.2018.11.008_bib41","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","article-title":"Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia","volume":"65","author":"Shimakawa","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib42","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/gast.2003.50053","article-title":"Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers","volume":"124","author":"Kao","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib44","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2018.11.008_bib45","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1542-3565(03)00293-3","article-title":"Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma","volume":"2","author":"Chen","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2893.2006.00776.x","article-title":"Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma","volume":"14","author":"Lin","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib48","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma","volume":"51","author":"Wu","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib49","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/djp180","article-title":"Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis","volume":"101","author":"Liu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2018.11.008_bib50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2014-306977","article-title":"Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers","volume":"64","author":"Tseng","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12985-015-0313-5","article-title":"Associations between hepatitis B virus basal core promoter\/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis","volume":"12","author":"Hu","year":"2015","journal-title":"Virol J"},{"key":"10.1016\/j.jfma.2018.11.008_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1053\/j.gastro.2006.01.011","article-title":"Higher prevalence and mapping of pre-S deletion in chronic hepatitis B virus carriers with cirrhosis and hepatocellular carcinoma","volume":"130","author":"Chen","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib53","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1440-1746.2006.04515.x","article-title":"Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma","volume":"22","author":"Lin","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2014.02.029","article-title":"Prospective evaluation of FibroTest\u00ae, FibroMeter\u00ae, and HepaScore\u00ae for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C","volume":"61","author":"Leroy","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-230X-12-14","article-title":"Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis","volume":"12","author":"Jin","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/MCG.0000000000000250","article-title":"Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B","volume":"49","author":"Lin","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Association Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib58","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ultrasmedbio.2015.03.007","article-title":"WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver","volume":"41","author":"Ferraioli","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jfma.2018.11.008_bib59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/apt.13488","article-title":"Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B","volume":"43","author":"Li","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/apt.12559","article-title":"Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B","volume":"39","author":"Wong","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ultrasmedbio.2014.07.018","article-title":"Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B","volume":"41","author":"Zhang","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jfma.2018.11.008_bib62","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib63","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","article-title":"Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"28","author":"Yang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib64","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib65","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2018.11.008_bib66","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cgh.2015.10.033","article-title":"Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis","volume":"14","author":"Yang","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"Wong","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B: a risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cgh.2011.12.019","article-title":"Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B","volume":"10","author":"Yang","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2012.12.006","article-title":"A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection","volume":"58","author":"Liu","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27083","article-title":"Distinct seromarkers predict different milestones of chronic hepatitis B progression","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib72","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib73","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/infdis\/jiu659","article-title":"Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: external Validation of a Scoring System","volume":"211","author":"Liu","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib75","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ajg.2017.254","article-title":"Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma","volume":"112","author":"Tseng","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib76","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/apt.14619","article-title":"Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection","volume":"47","author":"Tseng","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib78","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12072-007-9022-5","article-title":"Sustained response to peginterferon alfa-2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B","volume":"2","author":"Piratvisuth","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib80","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib81","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2016.05.024","article-title":"Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: a randomized controlled study","volume":"65","author":"Sun","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib83","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib84","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","article-title":"Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis","volume":"46","author":"Buster","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib88","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib90","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965350801300217","article-title":"Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence","volume":"13","author":"Wiegand","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib92","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3851\/IMP1841","article-title":"Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy","volume":"16","author":"Tseng","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib93","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib94","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcv.2009.07.005","article-title":"Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B","volume":"46","author":"Tangkijvanich","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jfma.2018.11.008_bib96","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/hep.26121","article-title":"Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion","volume":"57","author":"Yang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib97","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib98","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib99","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.24136","article-title":"Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients","volume":"53","author":"Piratvisuth","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib101","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib102","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","article-title":"Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"35","author":"Peng","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib103","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2011.11.025","article-title":"Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B","volume":"142","author":"Sonneveld","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.25749","article-title":"IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B","volume":"57","author":"Lampertico","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib106","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.12631","article-title":"Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?","volume":"39","author":"Galmozzi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib107","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ng.348","article-title":"A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians","volume":"41","author":"Kamatani","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2018.11.008_bib108","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/hepr.12284","article-title":"Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients","volume":"44","author":"Cheng","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2018.11.008_bib109","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/apt.12910","article-title":"Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B","volume":"40","author":"Brouwer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib111","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib112","article-title":"CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2018.11.008_bib113","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib114","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2018.11.008_bib115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumerate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib116","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib117","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/liv.12694","article-title":"Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (\u2265 9 log10 copies\/ml)","volume":"35","author":"Fung","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib118","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib119","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib120","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib121","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib122","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib123","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3851\/IMP2649","article-title":"Tenofovir-associated Fanconi syndrome in patients with hepatitis B monoinfection","volume":"18","author":"Gracey","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib124","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","article-title":"Randomized comparison of tenofovir disoproxil fumarate vs. emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B","volume":"146","author":"Fung","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib125","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/liv.12343","article-title":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D","volume":"34","author":"Liu","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"Van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib127","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2010.06.053","article-title":"Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection","volume":"139","author":"Berg","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib128","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","article-title":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","volume":"60","author":"Berg","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib129","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2011.09.018","article-title":"Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients. An international multicenter cohort study","volume":"56","author":"Petersen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib131","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib132","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib133","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitisB virustherapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2018.11.008_bib134","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir,cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib136","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, Phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib137","first-page":"62","article-title":"Chronic hepatitis B: an update","volume":"50","author":"Lok","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib138","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib139","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib140","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-na\u0131\u00a8ve chronic hepatitis B patients: viral suppression, viral resistance and clinical safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib141","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib142","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2009.12.036","article-title":"Long-term use of entecavir in nucleoside-na\u00efve Japanese patients with chronic hepatitis B infection","volume":"52","author":"Yokosuka","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib143","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib144","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00535-015-1128-2","article-title":"Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability","volume":"51","author":"Seto","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u0131\u00a8ve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib146","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.26910","article-title":"Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib147","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir Treatment for Chronic Hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib148","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/jvh.12239","article-title":"Antiviral effect of entecavir in nucleos(t)ide analogue-na\u00efve and -experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy","volume":"12","author":"Chen","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib149","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib151","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib152","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib153","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"For the VIRGIL Surveillance Study Group. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib154","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/jac\/dkt147","article-title":"Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants","volume":"68","author":"Yang","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jfma.2018.11.008_bib155","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"Kim","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib156","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2893.2011.01533.x","article-title":"Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir","volume":"19","author":"Pan","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib157","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s10620-012-2402-2","article-title":"Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders","volume":"57","author":"Yip","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2018.11.008_bib158","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib159","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in hepatitis B e antigen-negative chronic hepatitis B Asian patients: a multicenter prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib160","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic HBV infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib161","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/apt.13409","article-title":"Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis","volume":"42","author":"Chen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib162","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jgh.12416","article-title":"Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na\u00efve Taiwanese patients with chronic hepatitis B","volume":"29","author":"Chien","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib163","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib164","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","article-title":"The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound","volume":"48","author":"Warner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib165","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib166","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib167","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2010.06.043","article-title":"Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B","volume":"54","author":"Wong","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2018.11.008_bib168","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.12069","article-title":"Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance","volume":"33","author":"Zoulim","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib169","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib170","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/ajg.2011.253","article-title":"Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment","volume":"106","author":"Fung","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib171","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s12072-013-9440-5","article-title":"A comparison of four-year entecavir efficacy in nucleos(t)ide analogue-na\u00efve and -experienced adult Taiwanese chronic hepatitis B patients","volume":"7","author":"Chen","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib172","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jgh.12728","article-title":"Safety and efficacy of entecavir in adefovir-experienced patients","volume":"30","author":"Nguyen","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib173","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1128\/AAC.00587-13","article-title":"Randomized trial of virological response during up to two years of entecavir-adefovir combination therapy in multi-drug-refractory chronic hepatitis B virus patients","volume":"57","author":"Lim","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2018.11.008_bib174","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/17474124.2015.960398","article-title":"Improving clinical outcomes of chronic hepatitis B virus infection","volume":"9","author":"Su","year":"2015","journal-title":"Expet Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib175","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib176","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"Honer zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib177","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhosis HBeAg-negative patients-FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib178","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1053\/j.gastro.2018.03.066","article-title":"HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients","volume":"154","author":"Liaw","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib179","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jfma.2018.11.008_bib180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jfma.2018.11.008_bib181","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/jhep.2001.23045","article-title":"Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitisB: new perspectives for immune therapy","volume":"33","author":"Boni","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib182","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib184","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","article-title":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy","volume":"62","author":"Marcellin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib185","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3851\/IMP1466","article-title":"A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B","volume":"14","author":"Piccolo","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib186","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/jhep.2001.26819","article-title":"Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study","volume":"34","author":"Serfaty","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib187","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib188","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib189","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jfma.2017.12.007","article-title":"Phase IV randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B","volume":"117","author":"Hsu","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2018.11.008_bib190","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1440-1746.2007.05103.x","article-title":"Lamivudine\/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B","volume":"22","author":"Vassiliadis","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib191","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2036.2006.02731.x","article-title":"A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B","volume":"23","author":"Manesis","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib192","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib193","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/135965350701200507","article-title":"Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B","volume":"12","author":"Chan","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib194","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jvh.12418","article-title":"Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis","volume":"23","author":"Kim","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib196","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.3390\/ijerph120810039","article-title":"A better antiviral efficacy found in nucleos(t)ide analog (NA) combinations with interferon therapy than NA monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis","volume":"12","author":"Wei","year":"2015","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.jfma.2018.11.008_bib197","article-title":"The efficacy and safety of entecavir and interferon combination therapy for chronic hepatitis B virus infection: a meta-analysis","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2018.11.008_bib198","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/jvh.12379","article-title":"Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection","volume":"22","author":"Han","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.008_bib199","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.27837","article-title":"Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus","volume":"62","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib200","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib202","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1442-200x.2005.02101.x","article-title":"Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients","volume":"47","author":"Ni","year":"2005","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib203","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1478-3231.2008.01746.x","article-title":"Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan","volume":"28","author":"Hsu","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib204","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1442-200X.2010.03110.x","article-title":"Lamivudine treatment in infantile fulminant hepatitis B","volume":"52","author":"Chen","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.pedneo.2015.09.009","article-title":"Entecavir treatment in children and adolescents with chronic hepatitis B virus infection","volume":"57","author":"Chang","year":"2016","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib206","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo- controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib207","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2005.09.020","article-title":"Combined lamivudine\/interferon-alpha treatment in \u201cimmunotolerant\u201d children perinatally infected with hepatitis B: a pilot study","volume":"148","author":"D'Antiga","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.jfma.2018.11.008_bib208","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C\/hepatitis B co-infection versus those with chronic hepatitis C monoinfection","volume":"136","author":"Liu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib209","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/hep.26266","article-title":"Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up","volume":"57","author":"Yu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib210","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/gutjnl-2012-304370","article-title":"Treatment of patients with dual hepatitis C and B by peginterferon alfa and ribavirin reduced risk of hepatocellular carcinoma and mortality","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib211","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Longterm benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib212","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11908-012-0307-z","article-title":"Treatment options for hepatitis delta virus infection","volume":"15","author":"Heidrich","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jfma.2018.11.008_bib213","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib214","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jfma.2013.05.011","article-title":"Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir","volume":"114","author":"Chen","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2018.11.008_bib215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jcv.2009.09.027","article-title":"Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtrictabine","volume":"47","author":"Mansour","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jfma.2018.11.008_bib216","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3851\/IMP1630","article-title":"Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy","volume":"15","author":"Tuma","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib217","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2010.04.041","article-title":"Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study","volume":"53","author":"Piroth","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib218","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV infected adults","volume":"9","author":"Rockstroh","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib219","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","article-title":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus","volume":"139","author":"de Vries-Sluijs","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib220","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir\u2014effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2018.11.008_bib221","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerasemutations in HIV coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib222","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1086\/593105","article-title":"Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions","volume":"47","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib223","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcv.2011.07.014","article-title":"HIV\u2013HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir\/emtricitabine without antiviral resistance","volume":"52","author":"Schirmera","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jfma.2018.11.008_bib224","first-page":"173","article-title":"Immunizations in HIV infected adults","volume":"9","author":"Rivas","year":"2007","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jfma.2018.11.008_bib225","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2018.11.008_bib226","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib227","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","article-title":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B","volume":"38","author":"Chien","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib228","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","article-title":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B","volume":"8","author":"Jeng","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib229","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2018.11.008_bib230","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib231","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2014.02.013","article-title":"Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation","volume":"60","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib232","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib233","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib234","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib235","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib236","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1128\/AAC.03845-14","article-title":"Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains","volume":"58","author":"Lee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2018.11.008_bib237","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib238","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib239","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2018.11.008_bib240","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib241","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib242","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib243","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib244","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2018.11.008_bib245","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib246","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib247","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib248","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib249","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2011.10.011","article-title":"Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept","volume":"56","author":"Germanidis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib250","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/liv.12213","article-title":"The role of mTOR inhibitors in the treatment of hepatocellular carcinoma","volume":"33","author":"Huang","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib251","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2018.11.008_bib252","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2018.11.008_bib253","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.3748\/wjg.v12.i48.7725","article-title":"New insights into the coagulopathy of liver disease and liver transplantation","volume":"12","author":"Senzolo","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib254","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(92)90138-F","article-title":"Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications","volume":"14","author":"O'Grady","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib255","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/lt.20217","article-title":"Outcome of liver transplantation for hepatitis B in the United States","volume":"10","author":"Kim","year":"2004","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib256","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","article-title":"Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients","volume":"337","author":"Samuel","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.008_bib257","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.510280241","article-title":"Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin","volume":"28","author":"Markowitz","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib258","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/lt.23690","article-title":"Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B","volume":"19","author":"Perrillo","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib259","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","article-title":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis","volume":"48","author":"Angus","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib260","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/lt.23600","article-title":"Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates","volume":"19","author":"Gane","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib261","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib262","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib263","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/lt.20402","article-title":"Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence","volume":"11","author":"Marzano","year":"2005","journal-title":"Liver Transplant"},{"issue":"Suppl. 8","key":"10.1016\/j.jfma.2018.11.008_bib264","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/01.tp.0000446278.43804.f9","article-title":"Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation","volume":"97","author":"Hu","year":"2014","journal-title":"Transplantation"},{"issue":"Suppl. 2","key":"10.1016\/j.jfma.2018.11.008_bib265","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1002\/lt.21616","article-title":"How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting","volume":"14","author":"Lok","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib266","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2008.02.064","article-title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","volume":"134","author":"Faria","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib267","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2008.02.055","article-title":"Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis","volume":"6","author":"Loomba","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib268","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1432-2277.2008.00784.x","article-title":"Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis","volume":"22","author":"Rao","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib269","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1399-3062.2009.00470.x","article-title":"Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin,antiviral drugs, or both? Systematic review and meta-analysis","volume":"12","author":"Katz","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib270","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1872-034X.2012.01020.x","article-title":"Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation","volume":"43","author":"Ueda","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2018.11.008_bib271","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib272","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0168-8278(01)00039-3","article-title":"Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation","volume":"34","author":"Naoumov","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib273","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.tp.0000277289.23677.0a","article-title":"Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence","volume":"84","author":"Buti","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jfma.2018.11.008_bib274","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0168-8278(03)00087-4","article-title":"A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation","volume":"38","author":"Buti","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib275","series-title":"Hepatitis B virus in human diseases. Molecular and translational medicine","first-page":"361","article-title":"Organ transplanation in HB-infected patients","author":"Hu","year":"2016"},{"key":"10.1016\/j.jfma.2018.11.008_bib276","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcv.2013.06.035","article-title":"Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective","volume":"58","author":"Wesdorp","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jfma.2018.11.008_bib277","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1155\/2014\/839014","article-title":"One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation","volume":"28","author":"Tanaka","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib278","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/tri.12370","article-title":"New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib279","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.transproceed.2012.05.077","article-title":"Liver transplantation from hepatitis B surface antigen-positive donors","volume":"45","author":"Saidi","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jfma.2018.11.008_bib280","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/lt.21998","article-title":"Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review","volume":"16","author":"Saab","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib281","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","article-title":"Liver grafts from anti-hepatitis B core positive donors: a systematic review","volume":"52","author":"Cholongitas","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib282","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-6143.2006.01618.x","article-title":"Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients","volume":"7","author":"Lin","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib283","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/gut.50.1.95","article-title":"Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors","volume":"50","author":"Roque-Afonso","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.008_bib284","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840380407","article-title":"Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease","volume":"38","author":"Bienzle","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.03.013","article-title":"Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B","volume":"43","author":"Lo","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib286","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00535-010-0313-6","article-title":"Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts","volume":"46","author":"Ishigami","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.008_bib287","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/lt.20887","article-title":"Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors","volume":"13","author":"Luo","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib288","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/j.1600-6143.2005.01113.x","article-title":"HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib289","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib290","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000046265","article-title":"Long-term impact of hepatitis B, C virus infection on renal transplantation","volume":"21","author":"Lee","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jfma.2018.11.008_bib291","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2008.09.013","article-title":"The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients","volume":"50","author":"Tsai","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib292","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","article-title":"Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients","volume":"36","author":"Chan","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.008_bib293","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2215\/CJN.09201010","article-title":"Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States","volume":"6","author":"Reddy","year":"2011","journal-title":"CJASN"},{"key":"10.1016\/j.jfma.2018.11.008_bib294","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1310\/hct1506-231","article-title":"Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naive HIV-1 patients: meta-analysis of randomized clinical studies","volume":"15","author":"Winston","year":"2014","journal-title":"HIV Clin Trial"},{"key":"10.1016\/j.jfma.2018.11.008_bib295","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12072-011-9295-6","article-title":"The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up","volume":"6","author":"Hu","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.008_bib296","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3851\/IMP2097","article-title":"A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients","volume":"17","author":"Hu","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2018.11.008_bib297","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1469-0691.12220","article-title":"A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study","volume":"20","author":"Tsai","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jfma.2018.11.008_bib298","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jgh.12436","article-title":"Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis","volume":"29","author":"Tsai","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib299","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007890-200102150-00008","article-title":"Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence","volume":"71","author":"Han","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jfma.2018.11.008_bib300","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/tid.12202","article-title":"Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection","volume":"16","author":"Cho","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib301","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1034\/j.1600-6143.2001.10214.x","article-title":"Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor","volume":"1","author":"Chung","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib302","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1600-6143.2009.02707.x","article-title":"Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center","volume":"9","author":"Jiang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib303","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","article-title":"Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature","volume":"14","author":"Mahboobi","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib304","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0012.2009.01090.x","article-title":"Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B","volume":"24","author":"Tse","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2011.09.016","article-title":"Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool","volume":"56","author":"Loggi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.008_bib306","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1053-2498(00)00142-X","article-title":"Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT\/UNOS thoracic registry","volume":"19","author":"Hosenpud","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib307","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/gast.2000.17951","article-title":"Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival","volume":"119","author":"Lunel","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.008_bib308","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.athoracsur.2005.12.026","article-title":"Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation","volume":"81","author":"Shitrit","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jfma.2018.11.008_bib309","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/496924","article-title":"Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature","volume":"41","author":"Kempinska","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2018.11.008_bib310","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1600-6143.2005.00887.x","article-title":"Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors","volume":"5","author":"Hui","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2018.11.008_bib311","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10561-012-9326-0","article-title":"Comparative infectious serology testing of pre- and post-mortem blood samples from cornea donors","volume":"13","author":"Wilkemeyer","year":"2012","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.jfma.2018.11.008_bib312","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jfma.2018.08.020","article-title":"Hepatitis B: from control to cure","volume":"117","author":"Kao","year":"2018","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461830737X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966461830737X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:33:47Z","timestamp":1775295227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966461830737X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":312,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S092966461830737X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2018.11.008","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taiwan consensus statement on the management of chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}